Last reviewed 2026-05-23 · How we verify

Obizur (SUSOCTOCOG ALFA)

Baxalta Innovations GmbH · FDA-approved approved Recombinant protein Under review Quality 13/100

Obizur (generic name: SUSOCTOCOG ALFA) is a Recombinant protein drug developed by Baxalta Innovations GmbH. It is currently FDA-approved (first approved 2015) for Acquired factor VIII deficiency disease.

Obizur is an exogenous protein used to treat hemophilia A, and it works by replacing the coagulation factor VIII. It is administered to patients with severe hemophilia A.

At a glance

Generic name	SUSOCTOCOG ALFA
Sponsor	Baxalta Innovations GmbH
Modality	Recombinant protein
Therapeutic area	Hematology
Phase	FDA-approved
First approval	2015

Approved indications

Acquired factor VIII deficiency disease

Common side effects

No common side effects on file.

Key clinical trials

A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A

Patents

Patent	Expiry	Type
		Biologic Exclusivity

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results
FDA Orange Book	Patents + exclusivity

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Obizur CI brief — competitive landscape report
Obizur updates RSS · CI watch RSS
Baxalta Innovations GmbH portfolio CI

Frequently asked questions about Obizur

What is Obizur?

Obizur (SUSOCTOCOG ALFA) is a Recombinant protein drug developed by Baxalta Innovations GmbH, indicated for Acquired factor VIII deficiency disease.

What is Obizur used for?

Obizur is indicated for Acquired factor VIII deficiency disease.

Who makes Obizur?

Obizur is developed and marketed by Baxalta Innovations GmbH (see full Baxalta Innovations GmbH pipeline at /company/baxalta-innovations-gmbh).

What is the generic name of Obizur?

SUSOCTOCOG ALFA is the generic (nonproprietary) name of Obizur.

When was Obizur approved?

Obizur was first approved on 2015.

What development phase is Obizur in?

Obizur is FDA-approved (marketed).

Manufacturer: Baxalta Innovations GmbH — full pipeline
Therapeutic area: All drugs in Hematology
Indication: Drugs for Acquired factor VIII deficiency disease

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing